| Literature DB >> 30481525 |
Hardik Majmudar1, Meng Hao1, Nehru Viji Sankaranarayanan2, Brian Zanotti1, Michael V Volin1, Umesh R Desai2, Vaibhav Tiwari3.
Abstract
Herpes simplex virus type-1 (HSV-1) is a significant pathogen that affects vision by targeting multiple regions in the human eye including iris. Using a focused library of synthetic non-saccharide glycosaminoglycan mimetics (NSGMs), we identified sulfated pentagalloylglucoside (SPGG) as a potent inhibitor of HSV-1 entry and cell-to-cell spread in the primary cultures of human iris stromal (HIS) cells isolated from eye donors. Using in vitro β-galactosidase reporter assay and plaque reduction assay, SPGG was found to inhibit HSV-1 entry in a dosage-dependent manner (IC50 ∼6.0 μM). Interestingly, a pronounced inhibition in HSV-1 entry and spread was observed in HIS cells, or a cell line expressing specific gD-receptor, when virions were pre-treated with mimetics suggesting a possible interaction between SPGG and the HSV-1 glycoprotein. To examine the significance of gD-SPGG interaction, HIS cells were pretreated with SPGG, which showed a significant reduction in gD binding. Taken together, our results provide strong evidence of SPGG being a novel viral entry inhibitor against ocular HSV infection.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30481525 DOI: 10.1016/j.antiviral.2018.11.007
Source DB: PubMed Journal: Antiviral Res ISSN: 0166-3542 Impact factor: 5.970